Phase 3 N=81 Nicotine Lozenge or Tobacco-Free Snuff for Smokeless Tobacco Reduction
Tobacco Dependence
Primary: Tobacco Abstinence at 12 Weeks — 8; 5 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=232 UW Withdraw From Tobacco Study
Tobacco Dependence
Primary: Change in Total Score on Wisconsin Smoking Withdrawal Scale2 Long (WSWS2-L) — 2.64; 2.36; 2.29; 2.69 score on a scale
N/A N=34 Youth Smoking Cessation: Therapy +/- "The Patch"
Smoking
Primary: Acceptance of Nicotine Replacement Therapy — 26 participants
Phase 4 N=179 Smoking Tobacco and Drinking Study
Smoking · Heavy Episodic Drinking
Primary: Number of Participants With Reported 7-day Point Prevalence Abstinence at 3 Months — 3; 4 Participants
Phase 4 N=820 Smokers' Health Project: Self-Determination and Maintaining Tobacco Abstinence
Tobacco Use Disorder
Primary: 12 Month Prolonged Abstinence From Tobacco Measured at 12 Months From Completion of Intervention. — 169; 321; 318 participants
Phase 3 N=216 Maintaining Nonsmoking
Nicotine Dependence
Primary: Number of Participants With Reported 7-day Point Prevalence Abstinence at Week 12 — 22; 20; 29; 20 Participants
Phase 3 N=52 Highdose Nicotine Patch Therapy for Smokeless Tobacco Use
Smokeless Tobacco Use
Primary: End of Treatment (Week 8) Point Prevalence Abstinence — 11; 6 participants — p=0.05
N/A N=56 Tobacco Cessation Tailored to Patients Living With HIV (PLWH) in Brazil
HIV Infections · Tobacco Use Cessation
Primary: Number of Participants With a 7-day Prevalence Abstinence of Tobacco Use — 27 participants
N/A N=76 Varenicline for the Treatment of Smokeless Tobacco
Nicotine Dependence
Primary: 7-day Point Prevalence All Tobacco Abstinence — 21; 16 participants — p=0.126
Phase 2 N=391 Efficacy of Oral Tobacco Products Compared to a Medicinal Nicotine
Tobacco Use Disorder
Primary: Product Effect on Complete Substitution for Smoking — 56; 56 participants
N/A N=154 Enhancing a High School Based Smoking Cessation Program
Nicotine Dependence
Primary: Abstinence Rates at the End of Treatment — 35.1; 24.3; 38.6; 36.1 percentage of participants not smoking
Phase 3 N=270 Nicotine Lozenges for Treatment of Smokeless Tobacco Addiction
Smokeless Tobacco Use
Primary: Prolonged Smokeless Tobacco Abstinence at 3 Months — 65; 41 Participants — p=<0.05
N/A N=109 Tobacco Dependence Treatment for Asian Americans
Tobacco Dependence
Primary: 12-month Abstinence — 21; 6 Participants — p=<0.01
Phase 2 N=118 St. John's Wort for Tobacco Cessation
Smoking · Nicotine Dependence
Primary: Biochemically Confirmed 7-day Point Prevalence Abstinence From Tobacco — 7; 8; 6 participants — p=0.52
Phase 4 N=112 Smoking Cessation Treatment for Methadone Maintenance Patients
Smoking Cessation · Substance-Related Disorders
Primary: Biochemically Verified Abstinence Verified With Expired Carbon Monoxide (CO) < 8 p.p.m. — 6; 0 participants — p=0.03
Phase 2 N=746 Gradual vs. Abrupt Cessation Treatment for Smoking
Smoking Cessation
Primary: Number of Participants With Prolonged Abstinence Through 6 Months Verified by Carbon Monoxide Measurement — 12; 20; 7 participants — p=0.30
N/A N=104 Evaluation of Oral Tobacco as a Harm Reduction Method for Smokers
Tobacco Use Disorder
Primary: Product Preference — 27; 23; 24; 24 participants
Phase 2 N=332 Comparison Across Treatment Conditions to Reduce Smokeless Tobacco Use
Tobacco Use Disorder
Primary: Percent Abstinent From Tobacco at Week 12 (7 Day Point Prevalence) — 31; 17 percentage of randomized — p=0.04
Phase 4 N=30 Tobacco Cessation Treatment Preferences Among Veteran Smokers
Tobacco Use
Primary: Number of Participants Who Report Post-treatment Satisfaction — 15; 10 Participants
N/A N=40 QuitFast: Evaluating Transcranial Magnetic Stimulation as a Tool to Reduce Smoking Directly Following a Quit Attempt
Smoking · Smoking Cessation · Craving
Primary: Questionnaire on Smoking Urges Administered Daily Pre TMS to Measure Craving — 16; 12 units on a scale
N/A N=136 Reduced Nicotine Content Cigarettes and Tobacco Switching Behaviors
Tobacco Addiction · Dual Tobacco Use
Primary: Number of Days Using Alternative Products — 14; 26; 20 Number of days
N/A N=225 The Get Quit - Stay Quit Study
Nicotine Dependent Cigarette Smoker
Primary: Number of Participants Reporting no Tobacco Use in the Past 7 Days and Have a Validated CO <10ppm — 61; 55 Participants — p=.65
Phase 3 N=120 S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence
Tobacco Dependence
Primary: 7-day Point Prevalence Smoking Abstinence at End of Treatment (Week 8) — 7; 5; 7 participants — p=0.615
N/A N=31 Impact of Exclusive Use of Low Nicotine Cigarettes on Compensatory Smoking
Smoking
Primary: Breath Sample (Expired Carbon Monoxide) — 18.77; 31.07; 25.38; 30.49 parts per million — p=0.92
Phase 4 N=52 Tobacco Treatment Comparison for Cancer Care
Smoking Cessation · Cancer
Primary: Biochemically Verified 7-day Point-prevalence Abstinence 26 Weeks After a Target Quit Date. — 2; 7 Participants
N/A N=1,044 Implementation of HIT-Enhanced Tobacco Treatment for Hospitalized Smokers
Tobacco Use Cessation · Smoking Cessation · Smoking
Primary: Number of Participants With Exhaled Carbon Monoxide Confirmed Abstinence — 53; 65 participants
N/A N=310 Abstinence Reinforcement Therapy (ART) for Rural Veteran Smokers
Veteran · Smoking Cessation
Primary: Number of Participants With Abstinence or Non-Abstinence at 6-month Follow-up — 38; 40; 77; 83 Participants
N/A N=780 Treating Low-Income Smokers in the Hospital Emergency Department
Tobacco Use Cessation · Smoking Cessation · Smoking
Primary: Biochemical Verification of Tobacco Abstinence — 19; 47 participants
N/A N=51 Health-Kit Enabled Mobile App for Tobacco Cessation
Cigarette Smoking
Primary: Psychosocial Expectancies (PROMIS Smoking Initiative) Patient Reported Outcome — 12.7; 13.6 score on a scale — p=0.17
Phase 2 N=80 Testing Methylphenidate for Smoking Abstinence
Smoking
Primary: Number of Subjects Biochemically Confirmed to be Abstinent From Smoking at End of Treatment. — 1; 4 participants — p=0.973